Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
“ Mental given the investment case presented 3 years ago. So, again, given what price we should have been with a validated platform, your argument is nonsense. Nonsense.”
Wow chill out champ. I did not suggest the current valuation was correct or fair given the progress of the company.
You suggested the market conditions are the same as 2021 which is absolute rubbish. My argument was against that not whether the SP reflected true value.
“The market isn’t as dramatically different as people say it is, that’s just confirmation bias.”
Rubbish. AIM all share index has declined over 40% from its high in Jan 22. That is a huge flow of funds out of the market. Combined with rate rises and risk off growth the SP has held up well.
Sage Health Care lists Simon Bennett as an Executive Director.
https://www.sagehealthcare.com/simonbennett
Also note they are attending JPM conference in Jan.
“AS clearly states that they are wanting the phase 2 fortnightly study to commence early 2024 in the USA, with a view of completing 2 cohorts by june.”
He doesn’t say two cohorts. He clearly says 2 weekly study to complete end of second quarter.
“ You will now be aware that a hostile entity does not need to own a single share in a target company to launch a formal tender offer - which any BoD will be legally compelled to put to shareholders by the terms of the takeover code.”
😂 😂 No one responded because you clearly have no idea what you are talking about.
Companies are not legally required to put an offer to shareholders. A low ball offer by an entity with no significant holding is very easily defendable and would get laughed out the door by the takeover panel.
From the code…… “ Following an approach to the target board, the target will be responsible for making any required announcement unless it has unequivocally rejected any approach (in cases of doubt, the Panel should be consulted).”
AstraZeneca rejected Pfizer’s $100 billion bid and it never became public until 3 months later when Pfizer came clean!
Your idea of a tender offer is even more ridiculous. They very rarely occur in the UK, and generally only when a company is looking to buy back existing stock in the company. Hostile bids in the UK are also extremely rare with regulations protecting target boards.
If a company wants to make an attempt on Avacta at a valuation that the company rejects, the first shareholders will know about it is when the bidder leaks it in the city, and the SP will jump to whatever level the bid at. It will then be in Avacta’s court on how it plays out.
“This is where innovators become so emotionally attached to their creation they are unable to let it go.”
He didn’t create it he licensed in the Precision chemistry.
AS main failure is to get significant institutional buy in hence the ridiculous volatility. It will continue until this is sorted out. Plenty of AIM companies with strong IP (seeing Machines for example) have large institutional holdings. This needs to change for Avacta and soon. It will be imperative when takeover talks commence to extra maximum value.
Jive, at the presentation yesterday the patient with 65% reduction in tumour volume was on cohort 3 dosage, Chris C said patient had been on trial for “approaching 10 months”. This is well after cohort 3 had completed. This suggests that patient was added to the cohort after it completed!
I have messaged the company about UK trial screening.
It appears patients are being added to the trial after cohort completion.
Science day presentation - cohort 3 had 6 patients.
Yesterday’s presentation - cohort 3 had 8 patients
Science day - cohort 4 had 3 patients
Yesterday’s presentation - cohort 4 had 7 patients
Both cohorts had completed pre science day.
So appears they are adding patients after cohort completion or perhaps as toxicities emerge with patients still on drug.
Anyone aware if this is the case a whether patients in the UK will be able to access the trial under the current 1a cohort doses?
Slide 11 describes this perfectly and this appears completely missed by many yesterday.
Effectively dosing at 160mg/kg every 2 weeks gives the equivalent cumulative dosage that was given during cohort 5 in P1a.
The next 6 months with data emerging from this arm of the trial should be very exciting considering the current efficacy signals that have emerged.
1. Minimal grade 3-4 events observed across all cohorts vs. doxorubicin alone.
2. These severe toxicities limit doxorubicin dosing to every 3 weeks, however the reduction severe toxicities in severe toxicity with AVA6000 enables dosing optimisation to every 2 weeks.
3. >80% reduction across all dose levels of the maximal concentration (Cmax) and 40-80% reduction in total exposure (AUC) of released doxorubicin following AVA6000 dosing compared with standard dose doxorubicin.
Also the presentation next week is " a detailed review of the AVA6000 clinical trial's Phase 1a data".
Why are you expecting information on commercialisation? The company presented its future plans for its pipeline at the end of September.
Set expectations for a detailed review of data but if expecting more some may be disappointed.
The tender completion date has already been extended twice suggesting that not enough shares have been tendered for the deal to go through.
I expect it fails again tonight and they extend for go back to the drawing board.
Shareholders know they had a higher bidder conditional on pending phase 3 readout so expect they will hold onto their shares and follow BVF’s lead.
Targets were set in 2021 prior to war in Ukraine, inflation going through the roof and interest rates being hiked to highest levels in over a decade. Hopefully coming out the other side of that but unlikely in time to help with PM's options...... unless he can find a buyer.